title: Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
abstract: OBJECTIVE
  To investigate the relationship of 8-iso-prostaglandin (PG) F(2alpha) levels, a reliable marker of in vivo oxidative stress and lipid peroxidation, with bone mineral density (BMD), bone turnover markers, osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL) in hypercholesterolaemia.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  University hospital centre.
  
  
  METHODS
  Serum 8-iso-PGF(2alpha) levels were measured in 173 hypercholesterolaemic subjects and in 152 age- and sex-matched normocholesterolaemic controls. Femoral neck and lumbar spine BMD, serum bone-specific alkaline phosphatase (BAP), osteocalcin (OC), OPG and RANKL levels, as well as urinary levels of C-terminal telopeptides of type I collagen (CTX-I), were also assessed.
  
  
  RESULTS
  Hypercholesterolaemic subjects showed higher (P < 0.0001) serum 8-iso-PGF(2alpha) levels than controls. They also had decreased (P < 0.0001) femoral neck and lumbar spine BMD, and lower (P < 0.0001) serum BAP and OC levels. No significant differences between hypercholesterolaemic and control subjects were found when comparing urinary CTX-I levels, or serum OPG and RANKL levels. In multivariate linear regression analysis, serum 8-iso-PGF(2alpha) was the only negative predictor for femoral neck BMD and serum BAP and OC levels in hypercholesterolaemic subjects. No significant correlation (all P > 0.25) was present between serum 8-iso-PGF(2alpha) levels and urinary CTX-I levels, or serum OPG and RANKL levels, in hypercholesterolaemic subjects.
  
  
  CONCLUSIONS
  We found an association between increased serum 8-iso-PGF(2alpha) levels and lower bone mass and reduced serum BAP and OC concentrations in hypercholesterolaemic subjects. These results would suggest a possible role for oxidative stress in the development of lower bone mass in hypercholesterolaemia.
authors.affiliation: Department of Internal Medicine, University of Catania, Catania, Italy. rmangiafico@tiscali.it
authors.forename: R A
authors.initials: RA
authors.lastname: Mangiafico
authors.forename: G
authors.initials: G
authors.lastname: Malaponte
authors.forename: P
authors.initials: P
authors.lastname: Pennisi
authors.forename: G
authors.initials: G
authors.lastname: Li Volti
authors.forename: G
authors.initials: G
authors.lastname: Trovato
authors.forename: M
authors.initials: M
authors.lastname: Mangiafico
authors.forename: Y
authors.initials: Y
authors.lastname: Bevelacqua
authors.forename: F
authors.initials: F
authors.lastname: Mazza
authors.forename: C E
authors.initials: CE
authors.lastname: Fiore
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism* / Q000503:physiopathology; D003430:Cross-Sectional Studies; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism; D005260:Female; D005272:Femur Neck / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D006937:Hypercholesterolemia / Q000378:metabolism* / Q000503:physiopathology; D015227:Lipid Peroxidation; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015675:Osteocalcin / Q000097:blood; D053244:Osteoprotegerin / Q000097:blood; D018384:Oxidative Stress; D053245:RANK Ligand / Q000097:blood; D018709:Statistics, Nonparametric
chemical_list: D015415:Biomarkers; D053244:Osteoprotegerin; D053245:RANK Ligand; D015675:Osteocalcin; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; D000469:Alkaline Phosphatase